Tiziana Life Sciences to present Phase 2a MSA study at World Parkinson Congress

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday a late-breaking poster on its Phase 2a study of intranasal foralumab in Multiple System Atrophy (MSA) has been accepted for presentation at the World Parkinson Congress in Phoenix, Arizona in May 2026. The poster, titled “A Phase 2a Study of Intranasal Foralumab in Multiple System Atrophy,” will outline the design and rationale of the ongoing TILS-025 trial, the company said.